WEKO3
アイテム
Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans
https://doi.org/10.24517/00015372
https://doi.org/10.24517/00015372401441bc-639c-4c04-a16e-d8c272151273
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
PH-PR-KATO-Y-237.pdf (289.3 kB)
|
.png)
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2017-10-04 | |||||||||||||
| タイトル | ||||||||||||||
| タイトル | Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans | |||||||||||||
| 言語 | ||||||||||||||
| 言語 | eng | |||||||||||||
| 資源タイプ | ||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||
| 資源タイプ | journal article | |||||||||||||
| ID登録 | ||||||||||||||
| ID登録 | 10.24517/00015372 | |||||||||||||
| ID登録タイプ | JaLC | |||||||||||||
| 著者 |
Sugiura, Tomoko
× Sugiura, Tomoko× Takahashi, Saki× Sano, Kazusa× Abe, Tetsushi× Fukuta, Kazuhiro× Adachi, Kiichi× Nakamura, Toshikazu× 松本, 邦夫× Nakamichi, Noritaka× Kato, Yukio |
|||||||||||||
| 著者別表示 |
杉浦, 智子
× 杉浦, 智子
× 松本, 邦夫
× 中道, 範隆
× 加藤, 将夫
|
|||||||||||||
| 提供者所属 | ||||||||||||||
| 内容記述タイプ | Other | |||||||||||||
| 内容記述 | 金沢大学医薬保健研究域薬学系 | |||||||||||||
| 書誌情報 |
Journal of Pharmaceutical Sciences 巻 102, 号 1, p. 237-249, 発行日 2013-01-01 |
|||||||||||||
| ISSN | ||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||
| 収録物識別子 | 0022-3549 | |||||||||||||
| NCID | ||||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||||
| 収録物識別子 | AA00704450 | |||||||||||||
| DOI | ||||||||||||||
| 関連タイプ | isVersionOf | |||||||||||||
| 識別子タイプ | DOI | |||||||||||||
| 関連識別子 | 10.1002/jps.23337 | |||||||||||||
| 出版者 | ||||||||||||||
| 出版者 | American Pharmacists Association / Wiley-Blackwell | |||||||||||||
| 抄録 | ||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||
| 内容記述 | Hepatocyte growth factor (HGF) is under development for treatment of renal failure. This study was designed to clarify changes in HGF pharmacokinetics in renal failure and to establish a pharmacokinetic model applicable to single and repeated doses. The plasma concentration profile in mice with glycerol-induced acute renal failure was similar to that in normal mice, indicating a minimal contribution of kidney to systemic clearance of HGF. Nevertheless, accumulation of fluorescein-4-isocyanate-labeled HGF in renal tubules in both cases suggests the occurrence of efficient endocytosis of HGF in kidney. A pharmacokinetic model including plasma and liver compartments was constructed, incorporating both high- and low-affinity receptors for association and subsequent endocytosis of HGF because HGF is eliminated via specific receptor c-Met and heparin-like substance. The model well explained the plasma concentration profiles at all doses examined after bolus injection in animals and humans, and those during infusion in rodents. It includes externalization of receptors, which is negatively regulated by HGF, and can explain the gradual increase in trough concentration during repeated dosing in monkeys. Overall pharmacokinetic profiles of HGF are governed by at least two receptors and are well described by this pharmacokinetic model, which should assist in safe management of clinical trials. © 2012 Wiley Periodicals, Inc. | |||||||||||||
| 著者版フラグ | ||||||||||||||
| 出版タイプ | AM | |||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||||||||||
| 関連URI | ||||||||||||||
| 識別子タイプ | URI | |||||||||||||
| 関連識別子 | http://onlinelibrary.wiley.com/doi/10.1002/jps.23337/abstract | |||||||||||||
